Methylone, the White House Psychedelics Initiative Surprise
Methylone maybe the “post-MDMA” evolution of neuroplastogen psychiatry.
Posted May 26, 2026 | Reviewed by Michelle Quirk
From addictive and purposely misnamed “bath salts” sold in smoke shops to a possible future posttraumatic stress disorder ( PTSD ) treatment: Let’s talk about methylone. It’s a synthetic cathinone and structural cousin of MDMA (Molly, ecstasy) that may illustrate the emerging post-MDMA strategy in neuropsychiatry: preserving rapid neuroplastic and empathogenic effects while reducing the care complexity and regulatory vulnerabilities complicating the first generation of psychedelic-assisted therapy models. Methylone may represent the clearest example of where the field is heading after the Food and Drug Administration (FDA) rejection of MDMA-assisted psychotherapy in 2024.
The recent presidential executive order on psychedelics has prioritized psychedelic drugs with Breakthrough Therapy designation and National Priority Voucher eligibility. This has already dramatically influenced research priorities, regulatory momentum, investment, and clinical adoption . PTSD also remains inadequately treated, conventional antidepressants show only modest efficacy, and military trauma continues to impose enormous public health and disability burdens, particularly among veterans.
Methylone first emerged in the 2000s, marketed as a legal alternative to cocaine, methamphetamine, and MDMA. Which is precisely why methylone’s appearance in the recent White House discussion surrounding psychedelic medicine and mental-health innovation was very unexpected. In fact, the most surprising compound mentioned in the federal conversation wasn’t psilocybin, LSD, ibogaine, or even MDMA. It was methylone.
Historically viewed as a drug of abuse, methylone has unexpectedly entered mainstream psychiatric discussion following positive Phase 2 PTSD results for TSND-201, a pharmaceutical formulation developed by Transcend Therapeutics. A study just published in JAMA Psychiatry reported positive Phase 2 results for TSND-201. The study demonstrated statistically significant reductions in subjects' PTSD severity scores, along with improvements in their depressive symptoms and overall functioning.
Methylone is essentially β-keto-MDMA—a close structural cousin of MDMA. Like MDMA, it increases serotonin, dopamine , and norepinephrine signaling through monoamine transporter activity. Users historically described it as empathogenic, prosocial, and mood-elevating, although generally shorter-acting and somewhat more stimulant -like than MDMA.
But methylone differs from MDMA in several key ways. Importantly, it may be easier to use in conventional psychiatric settings. MDMA-assisted psychotherapy, as developed by MAPS and later Lykos Therapeutics, is highly resource-intensive. MDMA sessions often lasted 6–9 hours and required extensive monitoring, prolonged integration work, and multiple therapists. By comparison, methylone appears shorter-acting, somewhat more stimulant-like, and less emotionally immersive than MDMA.
The Post-MDMA Regulatory Shift
The modern psychedelic therapeutics landscape was largely shaped by the rise and subsequent regulatory challenges surrounding MDMA-assisted psychotherapy, which I covered in detail recently.
The FDA’s concerns about MDMA were not primarily about whether patients improved, but instead criticisms centered on trial design, data validity, and analysis. The FDA rejection of MDMA changed the psychedelic industry almost overnight.
Many investors and pharmaceutical strategists concluded the future might belong to compounds capable of preserving some of MDMA’s therapeutic biology but requiring much less operational complexity. Methylone fits closely with that development thesis.
What the New Methylone Study Showed
The Phase 2 IMPACT-1 trial enrolled 65 adults with severe PTSD in the United States, United Kingdom, and Ireland. Participants received four weekly oral dosing sessions of TSND-201. Unlike MDMA-assisted psychotherapy trials, patients did not undergo intensive trauma-processing psychotherapy. Instead, they received nondirective monitoring and facilitative supervision, but no elaborate therapeutic framework characteristic of the MAPS/Lykos model. That appears intentional and allowed the researchers to more directly evaluate whether methylone could demonstrate clinically meaningful PTSD efficacy alongside minimizing psychotherapy-related interpretability problems.
TSND-201 did produce statistically significant placebo -adjusted reductions in CAPS-5 PTSD severity scores. It showed a 9.64-point placebo-adjusted reduction on the CAPS-5 at day 64 in this randomized clinical trial. Improvements were also observed in depressive symptoms and functional impairment measures. Adverse effects were generally transient and manageable. Operationally, the sessions were substantially simpler than MDMA-assisted psychotherapy.
TSND-201 is being explored as a rapid neuropsychiatric intervention capable of producing neuroplastic emotion -processing effects with fewer logistical and psychotherapeutic demands than existing psychedelic-assisted approaches.
Unlike psilocybin, which primarily acts through 5-HT2A receptor agonism, or ketamine , which acts through glutamatergic neuroplasticity pathways, methylone primarily modulates serotonin, dopamine, and norepinephrine transporters. Preclinical studies also suggest methylone may enhance fear -extinction learning and upregulate neuroplasticity-related genes in frontal cortical regions and the amygdala—findings biologically relevant for PTSD and trauma therapeutics.
Despite mechanistic differences, methylone, ketamine, MDMA, and psilocybin may converge downstream on shared neuroplasticity pathways capable of producing rapid psychiatric effects.
How Methylone Differs From Existing Psychedelics
Psilocybin therapy generally relies on altered consciousness, extensive psychological preparation, and post-session integration. MDMA-assisted psychotherapy demonstrated strong efficacy in PTSD, but required prolonged treatment sessions, highly trained therapists, and intensive infrastructure. In contrast, methylone has a faster onset and shorter half-life. While MDMA sessions require intensive, prolonged 6- to 8-hour supervision, methylone sessions are significantly shorter (lasting roughly half as long).
Methylone appears capable of producing emotional openness and neuroplastic effects without fully hallucinogenic states. Compared with MDMA, methylone has a faster onset and shorter duration, potentially improving scalability, payer acceptance, and feasibility in standard outpatient settings.
That operational distinction may explain why mainstream pharmaceutical companies have become increasingly interested. Otsuka Pharmaceutical’s acquisition of Transcend Therapeutics signaled growing industry belief that psychedelic-adjacent therapeutics may be commercially viable if they remain regulatorily defensible and clinically manageable.
Why the Executive Order Matters
At first glance, methylone appeared the strangest compound mentioned in recent White House discussions surrounding psychiatric innovation. But its inclusion reflects a broader shift in how policymakers are beginning to think about PTSD, neuroplasticity, and next-generation psychiatric therapeutics.
Methylone may combine rapid psychiatric effects, neuroplasticity, and emotional-processing benefits with fewer logistical barriers than earlier psychedelic-assisted therapy models. Unlike highly immersive psychedelic protocols requiring extensive psychotherapy infrastructure, methylone-based approaches may prove easier to integrate into mainstream psychiatric practice.
Despite mounting enthusiasm for methylone and TSND-201, it is important to keep in mind that the current evidence base remains early-stage derived primarily from a small Phase 2 trial involving 65 participants. Larger Phase 3 studies are necessary to determine the durability of benefit, reproducibility across broader patient populations, comparative efficacy versus existing PTSD treatments, and long-term safety. Outside medical research settings, illicit methylone has historically been marketed as part of the “bath salts” synthetic cathinone market, associated with stimulant misuse, compulsive self-administration, and recreational abuse. Pharmaceutical TSND-201 is being developed for use under supervised dosing, medical observation, and standardized manufacturing conditions that differ substantially from illicit recreational use.
Cardiovascular and neuropsychiatric safety issues remain unresolved. Like MDMA and other monoaminergic agents, methylone increases serotonin, dopamine, and norepinephrine signaling and may potentially produce hypertension, tachycardia, anxiety , insomnia , or serotonergic toxicity in susceptible individuals or in combination with selective serotonin reuptake inhibitors (SSRIs) or other medications. It also remains to be proven whether methylone’s therapeutic effects can be reliably produced without accompanying psychotherapy or structured integration. Finally, the enthusiasm generated by recent federal attention , the FDA priority review announcement, and investment momentum should not be conflated with FDA approval, safety, or efficacy. Methylone remains an investigational compound, and major scientific, regulatory, and implementation questions remain unresolved.
Nevertheless, methylone’s rapid emergence from a stigmatized synthetic cathinone to a serious investigational PTSD therapy underscores how quickly neuropsychiatric and psychedelic medicine are evolving. If future studies confirm that diversion and misuse risks can be mitigated, methylone may help define the next generation of trauma therapeutics and accelerate the transition toward more practice-friendly neuroplasticity-based psychiatric treatments.
Jones A, Warner-Schmidt J, Kwak H, Stogniew M, Mandell B, Ching THW, Stein MB, Kelmendi B. Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial. JAMA Psychiatry. 2026 May 1;83(5):469–477. doi: 10.1001/jamapsychiatry.2025.4625. PMID: 41706459; PMCID: PMC12917749.
Watterson LR, Hood L, Sewalia K, Tomek SE, Yahn S, Johnson CT, Wegner S, Blough BE, Marusich JA, Olive MF. The Reinforcing and Rewarding Effects of Methylone, a Synthetic Cathinone Commonly Found in "Bath Salts." J Addict Res Ther. 2012 Dec 1;Suppl 9:002. doi: 10.4172/2155-6105.S9-002. PMID: 24244886; PMCID: PMC3828752.
Chou D, Peng HY, Lin TB, Hsieh MC, Lai CY, Lee CS. Methylone regulates fear memory and amygdala activity: A potential treatment for posttraumatic stress disorder? Prog Neuropsychopharmacol Biol Psychiatry. 2025 Jan 10;136:111201. doi: 10.1016/j.pnpbp.2024.111201. Epub 2024 Nov 23. PMID: 39581488.
Warner-Schmidt J, Stogniew M, Mandell B, Kelmendi B. Methylone promotes neurite outgrowth and has long-lasting effects on fear extinction learning. Neuropsychopharmacology. 2026 Feb;51(3):631-640. doi: 10.1038/s41386-025-02206-z. Epub 2025 Aug 23. PMID: 40849539; PMCID: PMC12823647.
Moreira M, Rocha V, Araújo AM, Carvalho M. From Euphoria to Cardiac Stress: Role of Oxidative Stress on the Cardiotoxicity of Methylone and 3,4-DMMC. Toxics. 2025 Nov 20;13(11):998. doi: 10.3390/toxics13110998. PMID: 41304552; PMCID: PMC12656588
Seaman RW Jr, Galindo DG, Stinson BT, Sulima A, Rice KC, Javors MA, Ginsburg BC, Collins GT. Cardiovascular and locomotor effects of binary mixtures of common 'bath salts' constituents: Studies with methylone, methylenedioxypyrovalerone and caffeine in rats. Br J Pharmacol. 2025 Apr;182(8):1836-1855. doi: 10.1111/bph.17444. Epub 2025 Jan 22. PMID: 39843219; PMCID: PMC12183792.
Share this post Facebook Bluesky Linkedin Email
There was a problem adding your email address. Please try again.
By submitting your information you agree to the Psychology Today Terms & Conditions and Privacy Policy
Mark S. Gold, M.D., is a pioneering researcher, professor, and chairman of psychiatry at Yale, the University of Florida, and Washington University in St Louis.
Get the help you need from a therapist near you–a FREE service from Psychology Today.
This article is part of the Bringwise Psychology Journal — daily insights on human behavior, mental health, and personal growth.